In conclusion, MMP-2, MMP-9, and NGAL levels seem to play a major role in the development of aneurysms, and their levels are modulated by statin treatment, suggesting that HMG-CoA reductase inhibitors have a role in the prevention of these clinical manifestations. The gene discussed is MMP9; the disease is aneurysm.